SEARCH

SEARCH BY CITATION

References

  • 1
    Prasad SM, Drazer MW, Hou D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012; 307: 16921694
  • 2
    Zeliadt SB, Hoffman RM, Etzioni R et al. Influence of publications of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 2011; 103: 520523
  • 3
    Wolters RJ, Spigt MG, Van Reedt Dorland PF, Gercema AJ, Klomp ML. NHG-Standard ‘Difficult voiding in older men’ (second revision). Huisarts Wet 2004; 47: 571586
  • 4
    Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 13201328
  • 5
    Van Weert H, Wiersma TJ. Prostate cancer screening? Not yet! Huisarts Wet 2009; 7: 350351
  • 6
    Centraal Bureau voor de Statistiek. Available at: http://www.cbs.nl. Accessed January 2013
  • 7
    Otto SJ, van der Cruijsen IW, Liem MK et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003; 105: 394399
  • 8
    Roobol MJ, van Vugt HA, Loeb S et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 2012; 61: 577583